New hope for tough lung cancer: ABBV-706 faces off against standard care
NCT ID NCT07365241
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new drug, ABBV-706, against standard treatments for small cell lung cancer that has come back or stopped responding. About 531 adults will receive either ABBV-706 or usual care (topotecan, lurbinectedin, or amrubicin) to see which works better. The goal is to shrink tumors and help people live longer.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Two-Pronged attack shrink Hard-to-Treat cancers?
- Can standard cancer treatment wake up the immune system? a study investigates.
- Experimental drug duo aims to boost immune attack on tough cancers
- Pinpoint radiation may spare the brain in lung cancer that spreads
- Rapid autopsy program aims to unlock secrets of aggressive lung cancer
- Mapping Cancer's evolution: a study to outsmart treatment resistance